Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus KETEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus KETEK.
CHLOROMYXIN vs KETEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Telithromycin binds to the 50S subunit of bacterial ribosome, inhibiting protein synthesis by blocking peptide chain elongation.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Telithromycin 800 mg orally once daily for 7-10 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal half-life (t½) is 9.8–10.6 hours in young healthy adults, allowing once-daily dosing. In elderly or severe hepatic impairment, t½ may be prolonged.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily fecal (≈70%) via biliary excretion of unchanged drug; renal excretion accounts for ≈13% (mostly unchanged), with additional minor metabolism (<30%).
Category C
Category C
Antibiotic
Antibiotic, Ketolide